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ization, and discount rate, were undertaken. RESULTS: In the
ﬁrst admission to perform PCI, the medical cost of the SES
patient was approximately 0.16m Japanese Yen higher than that
of the BMS patient. However, the expected three-year cumula-
tive medical cost per patient to be approximately 0.35m Yen
lower in the SES patient (2.07m Yen) than in the BMS patient
(2.43m Yen) because the revascularization rate was lower in the
SES patient. Extensive sensitivity analyses conﬁrmed that the
economic advantage of SES over BMS was quite robust. CON-
CLUSIONS: We concluded that the use of SES is likely to be a
cost-saving option as compared with BMS implantation within
the context of the Japanese health care system. Prospective eco-
nomic studies with long follow-up are needed to conﬁrm our
simulation results.
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OBJECTIVES: There are no published “real world” data for
costs of drug-eluting stenting procedures with the TAXUS 
Paclitaxel-Eluting Stent System. Whether Medicare payments
sufﬁciently cover costs of cases with comorbidities has not 
been investigated. METHODS: We analyzed resource utilization
data from ARRIVE, a prospective, multicenter, community-
hospital-based single arm US registry capturing 2590 consecu-
tive patients treated with the TAXUS stents at 50 sites. 
Procedural costs were calculated for subgroups with comorbidi-
ties of diabetes, renal disease, multivessel disease, congestive
heart failure, left main disease, acute myocardial infarction (MI),
and combinations of above conditions. Medical devices were
priced using 2004 national average prices, and procedural med-
ications using 2004 average wholesale prices. Hospitalization
costs were calculated using the 2003 MedPAR ﬁles, adjusted to
2004 costs. RESULTS: As shown in the table below, patients
with one or more comorbid conditions on average had higher
resource utilization and costs, ranging from $16,077 for left
main disease to $27,116 for renal disease (largely driven by the
length of stay). CONCLUSIONS: Stenting cases with severe
comorbidities incur higher costs than overall average. Average
Medicare payments in 2003 were $17,441 for patients with MI
(DRG 526) and $13,999 without MI (DRG 527). Clearly MI is
not the only comorbid condition that drives high inpatient costs.
The current DRG structure is not giving fair payments for
patients with certain high-cost comorbidities. 
PST3
COST-UTILITY OF STENTING FOR SYMPTOMATIC
INTRACRANIAL ATHEROSCLEROTIC DISEASE
Hornberger J1, Robertus K1, Deuber N2, Reyes CM3, Hernandez J3,
Bose A4
1The SPHERE Institute / Acumen, LLC, Burlingame, CA, USA;
2Boston Scientiﬁc Neurovascular, Fremont, CA, USA; 3Boston
Scientiﬁc Corporation, San Jose, CA, USA; 4New York University
(NYU) School of Medicine and SMART Therapeutics, New York, NY,
USA
OBJECTIVES: Symptomatic intracranial atherosclerosis (IA) has
an annual stroke risk of 5%–20%. The study objectives were: 1)
to assess economics of existing and emerging IA stenting (IAS)
technologies; and 2) estimate the effect of IAS versus anti-platelet
therapy (APL) on stroke risk, overall survival (OS), quality-
adjusted life years (QALYs), costs, and cost-utility (CU).
METHODS: A Markov model was developed to compare IAS
with APL from a US perspective in patients with symptomatic
IA. The model included the following parameters: 1) procedural
complications; 2) restenosis rates; 3) stroke rates of patent or
stenosed vessels; 4) mortality after stroke; 5) utilities; and 6)
costs of procedure, strokes, and unrelated future resource use.
Procedural outcomes of the current model are based on litera-
ture ﬁndings. Costs in $US 2004 and beneﬁts were discounted
at ﬁxed annual rate of 3%. Sensitivity analysis was also per-
formed on the above parameters. RESULTS: With IAS, 74% of
patients had patent vessel at six-months; 18% of patients expe-
rienced restenosis by 12 months, 11.3% of patients had a pro-
cedural complication (3.3% stroke, 6.3% non-stroke, 1.7%
death). Stroke risk is predicted to decline from 7.3%/yr from the
stenosed, target vessel to 0.5%/yr with patent vessel; and 5%/yr
stroke risk in non-target vessels. Over ﬁve years, stroke risk is
predicted to decline from 44% with APL to 31% for IAS. OS
thus is expected to increase by 0.33 years, and 0.24 QALYs. The
average cost per IAS procedure is $9,731, with a predicted
$8,366 reduction in stroke-related costs and cost-utility of IAS
vs APL of $19,963 over a 10-year time horizon. CONCLU-
SIONS: The cost-effectiveness model shows that IA stenting is
predicted to substantially reduce stroke rate, increase overall sur-
vival and QALY relative to antiplatelet therapy. The projected
CU ratio is considered within acceptable adoption ranges in the
US.
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DRUG-ELUTING VERSUS BARE-METAL CORONARY STENTS:
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OBJECTIVE: To evaluate the long-term outcomes of drug-
eluting stents in comparison to bare-metal stents in conventional
Renal Multivessel 
Overall Diabetes Disease Disease 
(n = 1968) (n = 586) (n = 48) (n = 707)
Proc. 
Duration 54.6 55.4 68.2 60.8
(min)
Stents 
implanted 1.7 1.71 1.65 1.82
Gp IIb/IIIa 35.3% 35.1% 28.4% 33.3%
Inhibitor
Length of 2.7 3 7.4 3
stay (days)
Total Cost $15,858 $16,641 $27,116 $17,131
Congestive Left Main >=1 
Heart Failure Disease Acute MI comorbidities
(n = 239) (n = 109) (n = 181) (n = 1223) 
Proc. 
Duration 60.4 64.4 57.1 57.0 
(min)
Stents 
implanted 1.7 1.7 1.7 1.7 
Gp IIb/IIIa 33.9% 41.6% 46.6% 34.7% 
Inhibitor
Length of 3.7 2.6 3.6 2.9 
stay (days)
Total Cost $18,520 $16,077 $18,162 $16,408
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treatment of coronary artery disease (CAD). METHOD: In 
this prospective comparative cohort study in 30 hospitals in
Germany, patients with coronary artery disease (CAD) undergo-
ing PTCA were electively treated with drug-eluting stents (DES)
or bare-metal stents (BMS). Standardized questionnaires com-
pleted by patients and physicians at 3, 6, 12, and 18 months 
following PTCA documented major adverse coronary events
(MACE), including death, myocardial infarct, coronary bypass
surgery and reintervention as well as direct and indirect costs
related to CAD. Patient health-related and disease-speciﬁc
quality of life was documented with the SF-36 and MacNew
heart disease questionnaires. RESULTS: From April until August
2004, 237 patients were treated with DES (88% male, mean age
63 ± 10) und 241 patients with BMS (82% male, mean age 65
± 10). There were no signiﬁcant differences in socio-demographic
factors, cardiovascular risk factors and severity of CAD. After 6
months, 11.6% of the DES cohort and 26.7% of the BMS cohort
had suffered a MACE (p < 0.05). The quality of life (SF-36 phys-
ical and mental summary scores and MacNew global score) at 3
months was higher in the DES cohort than in the BMS cohort
but at 6 months, both groups were similar. Initial hospital costs
were signiﬁcantly higher for DES than for BMS (6290 ± 1800
vs. 3655 ± 541 €, p < 0.001). The 6-month follow-up costs of
DES tended to be less than those of BMS (4305 ± 6031 vs. 5873
± 6442 €, p = n.s.). CONCLUSIONS: In comparison to patients
following BMS implantation, patients 6 months following
implantation of a DES have considerably fewer clinically rele-
vant adverse events, while the quality of life at this time point
was similar in both cohorts. Initial hospital costs were signiﬁ-
cantly higher for DES than for BMS but 6-month follow-up costs
were less for DES.
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OBJECTIVES: To estimate the economic burden of coded post-
operative ileus (POI) among patients undergoing open laparo-
tomies in the US. METHODS: Using Premier’s PerspectiveTM
database, we identiﬁed 193,409 open laparotomy surgical
patients based on their primary discharge ICD-9 procedure code
during 2002. Coded POI was identiﬁed using ICD-9 diagnosis
codes 560.1 and 997.4. Risk factors for coded POI were ana-
lyzed by a logistic regression model. To assess the economic
burden of coded POI, multiple regression analyses were per-
formed predicting hospital length of stay and total hospital costs
while controlling for baseline variables. Estimates of incremen-
tal costs and length of hospital stay were projected to the
national level. RESULTS: Extended operating room time
increased the risk of coded POI by 20% for each one-hour
increase (OR, 1.20, 95% CI, 1.19–1.21). Mean operating room
time was 3.0 ± 1.7 hours for patients with coded POI versus 2.5
± 1.2 hours for patients without coded POI. Use of PCA opioids
increased the risk of coded POI by 39% (OR, 1.39, 95% CI,
1.34–1.44). Coded POI was associated with an additional 2.6
days (P < 0.01) in the hospital and $1763 (P < 0.01) in total 
hospital costs. For the US, the overall burden of coded POI for
open laparotomies was estimated to be an additional 370,000
days in the hospital and $253 million in total costs. CONCLU-
SIONS: POI is associated with a signiﬁcant economic impact.
Inpatients with coded POI have extended operating time and
increased use of PCA opioids. POI was also associated with
increased hospital stay and consequently, hospital costs. Since
POI may not be routinely coded in this database, the true eco-
nomic burden of POI may be underestimated. Strategies to
reduce the impact of POI should lead to economic savings to the
hospital system.
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ELECTIVE SURGERIES IN THE US: RISK FACTORS, COST,
AND OUTCOMES
Saunders WB,Wang PF, Gaylord B
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OBJECTIVE: To determine the impact of age and gender on the
frequency and resource utilization among inpatients with a claim
for an elective surgery between October 2003 and September
2004 in the Premier Perspective Database. METHODS: All inpa-
tient and outpatient discharges with a claim for one of ﬁve elec-
tive surgeries between October 2003 and September 2004 were
retrieved. Procedures of interest were botox injections (botu-
linum toxin), liposuction (lipoplasty or lipectomy), nose reshap-
ing (rhinoplasty), breast augmentation (mammoplasty), and laser
treatment of leg veins (schlerotherapy or sclerosing). The rela-
tionship between each surgery and age, gender, length of stay,
and costs was examined, and the distinction between “elective”
and “necessary” surgeries is made where possible. RESULTS:
Overall, there were 2349 claims for botox injections (among
inpatients, 56% female; among outpatients, 62% female), 189
liposection procedures (over 91% females), 261 nose reshaping
procedures (55% male), 293 breast augmentations (over 96%
females), and 8,635 treatments of leg veins (among inpatients,
45% female; among outpatients, 50% female). With the excep-
tion of leg vein procedures, most were performed in hospital-
based outpatient clinics. Most botox procedures were performed
on females in outpatient clinic settings (n = 1177), and 9% were
performed on teens. Most liposection procedures were among
19–44 year-old females (57%) and middle-aged females (39%)
seen in outpatient clinics. In addition, most nose reshaping (more
common in males and teenagers received 10% of these proce-
dures) and breast augmentations occurred in the outpatient
setting (3% were among teens). Finally, most leg vein procedures
were among elderly inpatients, many of these non-elective surg-
eries. Additional results regarding the medications used, as well
as readmission, will be presented. CONCLUSION: Elective surg-
eries are common, and are captured in administrative hospital
data. Further research using data from specialty clinics should
be performed to better understand the magnitude and health
impacts associated with these procedures.
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OBJECTIVES: Numerous prescription products have become
available OTC in recent years and there are several reasons why
this number is likely to increase signiﬁcantly in the future. To
date, there have been simulation models, but no empirical assess-
ment of the impact of the Rx-to-OTC switch of loratadine. Pre-
